# Doxorubicin (Doxil) Combined With Rituxan, Cyclophosphamide, Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas

> **NCT00184002** · PHASE2 · COMPLETED · sponsor: **University of Southern California** · enrollment: 68 (actual)

## Conditions studied

- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** Doxorubicin, Rituxan, Cyclophosphamide, Vincristine and Prednisone

## Key facts

- **NCT ID:** NCT00184002
- **Lead sponsor:** University of Southern California
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-01-10
- **Primary completion:** 2012-12-19
- **Final completion:** 2013-05-07
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2017-08-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00184002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00184002, "Doxorubicin (Doxil) Combined With Rituxan, Cyclophosphamide, Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00184002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*